SUN13837

Cat. No.: HY-147681 Purity: 99.18%: Data Sheet
COA

SDS
Handling Instructions
FAQs
Technical Support

SUN13837 is an orally active, blood-brain barrier permeable FGFR modulator and neuroprotective agent. SUN13837 mimics the activity of basic fibroblast growth factor, stimulates intracellular tyrosine phosphorylation of FGFR and signal transduction in neuronal cells, induces neurite outgrowth, and inhibits glutamate-induced neuronal death. SUN13837 can be used in research related to acute cervical spinal cord injury and severe spinal cord injury.

For research use only. We do not sell to patients.

SUN13837 Chemical Structure

CAS No. : 1080650-67-4

Size		Stock
5 mg		Check price and availability
10 mg		Check price and availability
25 mg		Check price and availability
50 mg		Check price and availability

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

Biological Activity
Purity & Documentation
References
Customer Review

Description

In Vitro

SUN13837 (10 μM; 24 h pre-incubation before glutamate exposure) exhibits 100% neuroprotective activity against glutamate-induced cell death in rat embryonic cerebral cortex and hippocampal neurons^[2].
SUN13837 (10 μM; 30 min pre-incubation) inactivates CYP3A4 in a mechanism-based manner in liver microsomes, with residual activity of 60%^[2].
SUN13837 (10 μM; 120 min) is a substrate of P-gp, with an efflux ratio of 6.3 in Caco-2 cell monolayers^[2].
SUN13837 (100 μM; 60 min) undergoes hydrolysis by liver microsomes at a rate of 7.2 pmol/min/mg protein^[2].
SUN13837 (0.3-3 μM) potently induces axonal growth in primary hippocampal neurons from E18 Wistar rats. The effect produced by 3 μM SUN13837 is comparable to that of 3 ng/mL bFGF, and significant increases in axon length are observed at concentrations of 0.3 μM and 3 μM^[3].
SUN13837 (0.1-1 μM) protects primary hippocampal neurons from E18 Wistar rats against glutamate-induced cell death by activating FGFR-1, with significant neuroprotective effects observed at concentrations of 0.1 μM, 0.3 μM and 1 μM^[3].
SUN13837 (0.3-3 μM; 40 minutes) activates intracellular tyrosine phosphorylation via human FGFR-1 in transfected L6 rat skeletal muscle cells, with significant elevations observed at concentrations of 0.3 μM, 1 μM and 3 μM^[3].
SUN13837 (0.1-30 μM; 22-23 h) does not induce proliferation in SW1353 chondrosarcoma cells or Swiss 3T3 mouse embryonic fibroblasts, even at concentrations as high as 30 μM^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Proliferation Assay^[3]

Cell Line:	SW1353 human chondrosarcoma cells, Swiss 3T3 mouse embryo fibroblast cells
Concentration:	0.1 μM, 0.3 μM, 1 μM, 3 μM, 10 μM, 30 μM
Incubation Time:	22-23 h
Result:	Did not produce a significant increase in BrdU uptake in either SW1353 or Swiss 3T3 cells, with absorbance values remaining comparable to vehicle control levels. Contrasted with bFGF, which significantly increased BrdU uptake in both cell lines.

Western Blot Analysis^[3]

Cell Line:	Swiss 3T3 mouse embryo fibroblast cells
Concentration:	10 μM
Incubation Time:	16 h
Result:	Had no significant effect on cyclin D1 expression. Had no significant effect on p27(kip1) expression. Contrasted with bFGF, which increased cyclin D1 expression by 4.6-fold and decreased p27(kip1) expression to 5% of control levels.

Parmacokinetics

Species	Dose	Route	T_1/2	CL	V_d	AUC_0-∞	C_max
Rat^[2]	1 mg/kg	i.v.	1.4 h	2.5 L/h/kg	2.3 L/kg	/	/
Rat^[2]	10 mg/kg	p.o.	/	/	/	3704 ng·h/mL	70 ng/mL

In Vivo

SUN13837 (1 mg/kg; p.o.; daily; 10 days) significantly enhances recovery of coordinated movement in a rat acute stroke model, with efficacy comparable to analog compound 17 despite compound 17 having 6-fold higher estimated brain concentration^[2].
Systemic administration of SUN13837 (0.3-1 mg/kg; i.v.; daily; 10 days) starting up to 12 hours post-spinal cord injury significantly enhances hind limb motor function recovery (BBB score >12 at 8 weeks) and axon regeneration in rats without adverse events^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Slc: SD (female, 180-250 g, T9 spinal cord contusion injury model)^[3]
Dosage:	0.3 mg/kg (first dose 90 mins post-injury); 1 mg/kg (first dose 90 mins post-injury); 1 mg/kg (first dose 12 hours post-injury)
Administration:	i.v.; daily; 10 days
Result:	Showed significantly enhanced hind limb motor function from 2 weeks post-injury onward, reaching a BBB score >12 at 8 weeks (p = 0.017), compared to vehicle group's score of 8. Shortened MEP latency significantly (p = 0.0146) and increased MEP amplitude relative to vehicle. Had higher BBB scores than vehicle at all time points, but the difference did not reach statistical significance (p = 0.118). Showed significantly enhanced motor function recovery from 5 weeks post-injury onward, with a significant difference at 8 weeks (p = 0.025). Increased 5-HT-positive area 4 mm caudal to the contusion epicenter significantly (p = 0.0043 for 90-minute group, p = 0.027 for 12-hour group) relative to vehicle. Induced extensive caudal extension of corticospinal tract axons through the contusion site into lumbo-sacral spinal segments, whereas axon extension was limited to distal stumps in vehicle-treated rats.

Clinical Trial

Molecular Weight

383.49

Formula

C₂₁H₂₉N₅O₂

CAS No.

1080650-67-4

Appearance

Solid

Color

White to off-white

SMILES

CC1=NC(OCC(N(C2CCN(CC2)CC3=CC=CC=C3)C)=O)=NC(C)=C1N

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Solvent & Solubility

In Vitro:

DMSO : 50 mg/mL (130.38 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	2.6076 mL	13.0381 mL	26.0763 mL
5 mM	0.5215 mL	2.6076 mL	5.2153 mL
10 mM	0.2608 mL	1.3038 mL	2.6076 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (6.52 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (6.52 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 2.5 mg/mL (6.52 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Purity & Documentation

Purity: 99.18%

Select Batch:

Data Sheet (277 KB) SDS (252 KB)

COA (244 KB) HNMR (442 KB) LCMS (96 KB)

Handling Instructions (2659 KB)

References

[1]. Levinson B, et al. SUN13837 in treatment of acute spinal cord injury, the ASCENT-ASCI Study[J]. Clin Neurol Neurosci, 2018, 2(1): 1.

[2]. Sakai H, et al. Fibroblast growth factor receptor modulators employing diamines with reduced phospholipidosis-inducing potential. Bioorg Med Chem. 2020;28(14):115562. [Content Brief]

[3]. Imagama S, et al. Systemic treatment with a novel basic fibroblast growth factor mimic small-molecule compound boosts functional recovery after spinal cord injury. PLoS One. 2020;15(7):e0236050. Published 2020 Jul 17.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	2.6076 mL	13.0381 mL	26.0763 mL	65.1907 mL
	5 mM	0.5215 mL	2.6076 mL	5.2153 mL	13.0381 mL
	10 mM	0.2608 mL	1.3038 mL	2.6076 mL	6.5191 mL
	15 mM	0.1738 mL	0.8692 mL	1.7384 mL	4.3460 mL
	20 mM	0.1304 mL	0.6519 mL	1.3038 mL	3.2595 mL
	25 mM	0.1043 mL	0.5215 mL	1.0431 mL	2.6076 mL
	30 mM	0.0869 mL	0.4346 mL	0.8692 mL	2.1730 mL
	40 mM	0.0652 mL	0.3260 mL	0.6519 mL	1.6298 mL
	50 mM	0.0522 mL	0.2608 mL	0.5215 mL	1.3038 mL
	60 mM	0.0435 mL	0.2173 mL	0.4346 mL	1.0865 mL
	80 mM	0.0326 mL	0.1630 mL	0.3260 mL	0.8149 mL
	100 mM	0.0261 mL	0.1304 mL	0.2608 mL	0.6519 mL

SUN13837 Related Classifications

Neurological Disease

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

SUN138371080650-67-4SUN 13837SUN-13837FGFRFibroblast growth factor receptorglutamate-induced neuronal cell deathembryonic rat cerebrocortical neuronsbasic fibroblast growth factorfibroblast growth factor receptoracute cervical spinal cord injuryembryonic rat hippocampal neuronsCaco-2 cell monolayersspinal cord injurysevere spinal cord injuryCYP3A4Inhibitorinhibitorinhibit

Your Recently Viewed Products:

Product Name

Requested Quantity *

Applicant Name *

Salutation

Email Address *

Phone Number *

Department

Organization Name *

City

State

Country or Region *

Remarks

Product Name

Lot #

Applicant Name *

Email Address *

Phone Number

Department *

Organization Name *

Country or Region *

Remarks

SUN13837

SUN13837 Related Antibodies

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

Biological Activity

Purity & Documentation

References

Customer Review

SUN13837 Related Antibodies

Molarity Calculator

Dilution Calculator